Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 4.07M P/E - EPS this Y 105.60% Ern Qtrly Grth -
Income 2.67M Forward P/E -0.30 EPS next Y -265.20% 50D Avg Chg -37.00%
Sales 16.02M PEG - EPS past 5Y - 200D Avg Chg -83.00%
Dividend N/A Price/Book 0.11 EPS next 5Y - 52W High Chg -95.00%
Recommedations 1.70 Quick Ratio 19.02 Shares Outstanding 2.97M 52W Low Chg -
Insider Own 2.31% ROA 12.96% Shares Float 1.36M Beta -0.28
Inst Own 48.34% ROE 13.69% Shares Shorted/Prior 5.24K/9.17K Price 0.56
Gross Margin 71.31% Profit Margin 19.98% Avg. Volume 270,170 Target Price 30.33
Oper. Margin -12,123.26% Earnings Date Nov 7 Volume 93,777 Change -5.08%
About Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials indicated for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, currently under phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; KIO-101, an eye drop for the treatment of ocular presentation of rheumatoid arthritis; and KIO-201, an eye drop for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. It has commercialization agreement with 4SC Discovery GmbH, for KIO-101; and collaboration agreement with Théa Open Innovation for the development KIO-301. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

Kiora Pharmaceuticals, Inc. News
11/15/24 We Think Kiora Pharmaceuticals' (NASDAQ:KPRX) Healthy Earnings Might Be Conservative
11/08/24 Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies
10/30/24 Kiora Pharmaceuticals Gains Approval for Phase 2 Trial
10/29/24 Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa
09/25/24 Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences
08/09/24 Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies
07/30/24 Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies
07/10/24 Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation
07/01/24 Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors
06/25/24 Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board
06/18/24 Is Kiora Pharmaceuticals (KPRX) Stock Undervalued Right Now?
06/11/24 Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) stock most popular amongst retail investors who own 39%, while hedge funds hold 31%
05/29/24 Lytham Partners Spring 2024 Investor Conference Starts Tomorrow, May 30, 2024
05/10/24 Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease
05/08/24 Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference
05/06/24 Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain Activity in the Visual Cortex in Patients with Retinitis Pigmentosa
04/11/24 Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study
04/05/24 Kiora Pharmaceuticals to Present at Upcoming Investor Conferences
03/28/24 Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting
03/25/24 Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases
KPRX Chatroom

User Image Flowjob Posted - 9 hours ago

$INM $KPRX if you are invested here and have noticed the lack of volume on news, their press releases wont show up on Benzinga TradeIdeasNews and several other platforms. Something for these companies to look into GL

User Image TheButchers Posted - 5 days ago

$KPRX They only have cash because they completed horrific reverse split discounted financing. The management is the problem. Despite spending like drunken sailors over the past several years they only recently filed a U.S. IND. That is just the first step in getting clinical projects started in the US. They are a long ways off to getting anything approved for commercial sales. This is a disaster.

User Image vaselineguy Posted - 6 days ago

$KPRX I am in now

User Image Paper_Route_Frank Posted - 1 week ago

$KPRX been in this thing since majority of the year looks like the selling is exhausted

User Image Skichic Posted - 1 week ago

$KPRX Awesome looking financials, cash runway into 2027, 3 million share OS, $1.91 EPS (thanks to a large grant), this is the best looking biotech out there.

User Image KioraIR Posted - 1 week ago

$KPRX With the reporting of our Q3 results this morning, we provided an update on the progress of our development pipeline. We remain in a strong position with two innovative drug candidates entering Phase 2 trials. Our balance sheet is strong providing a runway beyond anticipated readouts for both studies. KIO-301 recently received approval to initiate ABACUS-2, a 36-patient controlled study in retinitis pigmentosa and we finalized the design of the Phase 2 KLARITY trial of KIO-104 for the treatment of retinal inflammatory diseases. We invite you to read more in our detailed earnings announcement > https://ir.kiorapharma.com/news-events/press-releases/detail/226/kiora-pharmaceuticals-reports-third-quarter-results

User Image newsfile_corp Posted - 1 week ago

https://nfne.ws/229204 $KPRX #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #Earnings #QuarterlyResults #Results #NASD

User Image KioraIR Posted - 2 weeks ago

$KPRX | ICYMI, Melissa Tosca's presentation from the LD Micro investor conference is now available on-demand (registration required). Key topics covered include the recent approval for the ABACUS-2 Ph 2 trial of KIO-301 for the treatment of RP and the plans for the KLARITY Ph 2 trial of KIO-104 for treatment of retinal inflammation. https://me24.sequireevents.com/

User Image JonTripathi Posted - 10/31/24

$KPRX position disclosure

User Image JonTripathi Posted - 10/30/24

$KPRX still within long-term bearish channel.

User Image TheButchers Posted - 10/30/24

$KPRX off balanced financing and heavy dilution of 3 decimating reverse splits does not bode well with this management. It is unbelievable after spending so much multiples of $5-10M recapitalization financings that they just recently have finally have the green light to start clinical trials under United States FDA regulations. This should have been completed within months of the merger with this failing management group. Still years away from completing any pivotal trial.

User Image Daniela999888 Posted - 10/29/24

$KPRX Target Price: 4.4 Stop Loss: 3.2 The overall trend is upward, with steadily rising lows and active price movement. The stock has strong fundamentals and is currently drawing market interest. The previous high is around 4.4, where there is significant resistance due to previous holding positions. For now, monitor whether it can break past this high after consolidation. If the price weakens at this level, consider partially taking profits. Currently, holding the position seems reasonable as there are no significant issues in the trend.

User Image Skichic Posted - 10/29/24

$KPRX It would be nice if people actually did DD. Analysts calling for $30.00+ here, which is conservative. OS less than 5 million!

User Image Skichic Posted - 10/29/24

$KPRX This is huge “In a short window since entering our partnership with Kiora, tremendous progress has been made on advancing KIO-301 toward ABACUS-2," said Dr. Céline Olmiere, Head of Théa Open Innovation. "What makes KIO-301 compelling is that it appears, based on the Phase 1b data, to have potential for meaningful vision restoration. Further, because of its unique mechanism of action, it has the potential to work across all 150-plus underlying gene mutations associated with retinitis pigmentosa and other inherited retinal diseases."

User Image _CHUPACABRA Posted - 10/29/24

$KPRX 47.86% tute owned 10.42% insider owned 9.37 cash/sh Per-Finviz Low float 🎯

User Image _CHUPACABRA Posted - 10/29/24

$KPRX Trying to get back over $4.00

User Image _www_larval_com_ Posted - 10/29/24

$KPRX has slipped -8% lower to -14% (~363Kv) moments ago, follow for more volatility.

User Image JonTripathi Posted - 10/29/24

$KPRX sell the news event Game over here

User Image Machiaveltrade Posted - 10/29/24

$KPRX took a position here …good short attack

User Image Sobac Posted - 10/29/24

$KPRX How can you cut it in half in a minute

User Image KioraIR Posted - 10/29/24

$KPRX This morning we announced that we received approval to initiate a Phase 2 clinical trial of KIO-301 in patients with retinitis pigmentosa. Our trial, called ABACUS-2, will be a randomized, double-masked study that will enroll 36 patients across leading retinal disease centers in Australia. More details in the following announcement > https://ir.kiorapharma.com/news-events/press-releases/detail/225/kiora-pharmaceuticals-receives-investigational-new-drug

User Image JonTripathi Posted - 10/29/24

$KPRX very strange price action

User Image Sobac Posted - 10/29/24

$KPRX dog shit

User Image Almos Posted - 10/29/24

$KPRX what would have caused that?

User Image dumbassbobby Posted - 10/29/24

$KPRX dog shit

User Image _CHUPACABRA Posted - 10/29/24

$KPRX Nice jump to 7.18

User Image Scanners_Free Posted - 10/29/24

$KPRX spike to 80% on nothing

User Image newsfile_corp Posted - 10/29/24

https://nfne.ws/228101 $KPRX #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #NASDAQ #Investing

User Image litzke83 Posted - 10/28/24

$KPRX thats the beginning!!!

User Image ZJ3001 Posted - 10/28/24

$KPRX let’s go! This float is tight!!! Been sitting on bid all morning.

Analyst Ratings
HC Wainwright & Co. Buy Aug 22, 24
HC Wainwright & Co. Buy Jul 23, 24
HC Wainwright & Co. Buy May 20, 24
HC Wainwright & Co. Buy Mar 27, 24
HC Wainwright & Co. Buy Feb 9, 24
HC Wainwright & Co. Buy Nov 13, 23
HC Wainwright & Co. Buy Nov 6, 23
HC Wainwright & Co. Buy Aug 24, 23
HC Wainwright & Co. Buy Aug 14, 23